Dosimetric predictors of biochemical control of prostate cancer in patients randomised to external beam radiotherapy with a boost of high dose rate brachytherapy
Hoskin PJ, Rojas AM, Ostler PJ, Hughes R, Bryant L, Lowe GJ. Radiother Oncol. 2013 Oct 4. pii: S0167-8140(13)00443-X. doi: 10.1016/j.radonc.2013.08.043. [Epub ahead of print]


Cancer Centre, Mount Vernon Hospital, Middlesex, UK.


BACKGROUND: To correlate dose and volume dosimetric parameters (D90 and V100) with biochemical control in advanced prostate cancer treated with high-dose rate brachytherapy (HDR-BT).

METHODS: One hundred and eight patients received external beam radiotherapy (EBRT) to 35.75Gy in 13 fractions followed by HDR-BT of 2×8.5Gy. Kaplan-Meier freedom-from-biochemical relapse (FFbR; nadir+2μg/L) fits were grouped by the first (Q1), second (Q2) and third (Q3) D90 and V100 quartiles. Groups were compared with the log-rank test. Univariate and multivariate Hazard Ratios (HR) for D90 and V100 and other co-variates (PSA, androgen deprivation therapy (ADT) were obtained using Cox's proportional hazard model.

RESULTS: FFbR was significantly higher in patients whose D90 and V100 were at or above the second and third quartile (log rank p⩽0•04). In multivariate analysis D90, V100 were significant covariates for risk of relapse.

CONCLUSIONS: Dichotomising the data using 6 levels of response (above and below Q1, Q2 and Q3) showed a progressive and continuous improvement in biochemical control of disease across the entire dose (and volume) range. The data show that a minimum D90 of 108% of the prescribed dose should be the target to achieve.